When inhibiting thyroid stimulating hormone for preventing thyroid cancer recurrent, caution must be taken to prevent bone fracture

The joint research team of professor Dong Wook Shin , Department of Family medicine, Samsung Medical Center, professor Young Min Park, National Health Insurance Service Ilsan Hospital, and CEO Beomseok Suh, Lunit, a medical IT company studied on 185,956 patients with thyroid cancer who were diagnosed between 2004 and 2012 based on the National Health Insurance Service statistics and compared them with the control group composed of the same size of the general population.
The research team studied whether mild hyperthyroidism that manifests when thyroid stimulation hormone (TSH) is administered to prevent recurrence after thyroid cancer surgery increases the bone fracture risk.
The research team divided the patients into four groups based on the administration doses of the thyroid hormone medication, assessed the number of bone fracture occurrences, and compared it with that of the control group. As the result, the patient group whose administration dose was highest (more than 170 microgram per day) had the increased bone fracture risk by 25% compared with the control group.
However, generally, the bone fracture occurrence risk of the patients with thyroid cancer was not higher than that of the control group, and for the patients that corresponded to the second group, the bone fracture occurrence risk was rather lower than that of the general population.
Professor Shin said, “Although there are cases that the dose of thyroid hormone needs to be increased slightly to prevent the thyroid cancer recurrence, caution must be taken because osteoporosis or bone fracture risk can be increased.”
Meanwhile, this research was published in a recent issue of “the Journal of Bone and Mineral Research (IF 6.314),” an international academic journal.